Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

[New targets for the prevention and treatment of cirrhotic portal vein thrombosis]

Management of Portal vein Thrombosis in Cirrhosis

Analysis of factors related to recanalization of portal vein thrombosis in liver cirrhosis: a retrospective cohort study

Classification and Management of Portal Vein Thrombosis in Cirrhotic Patients: A Narrative Review

Clinical characteristics and predictors of benign portal vein thrombosis in patients with liver cirrhosis: A retrospective single-center study

GSDMD-Dependent Neutrophil Extracellular Traps Mediate Portal Vein Thrombosis and Associated Fibrosis in Cirrhosis

Etiology and management of portal vein thrombosis：recent progress in research

Portal Vein Thrombosis: State-of-the-Art Review

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Increased Portal Vein Diameter is Predictive of Portal Vein Thrombosis Development in Patients with Liver Cirrhosis

Clinical analysis of portal vein thrombosis in patients with liver cirrhosis

A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat?

Updates in the Research of Portal Vein Thrombosis in Patients with Cirrhosis and Portal Hypertension after Splenectomy

Risk Factors of Portal Vein Thrombosis after Devascularization Treatment in Patients with Liver Cirrhosis: A Nested Case-Control Study

Prevalence and Clinical Characteristics of Advanced Portal Vein Thrombosis in Cirrhotic Patients with Gastroesophageal Variceal Hemorrhage.

Early Prophylactic Anticoagulation via Transjugular Intrahepatic Route for Portal Vein Thrombosis after Splenectomy in Cirrhotic Portal Hypertension

Liver Transplant Recipients with Portal Vein Thrombosis:A Single Center Retrospective Study

Platelet-derived TGF-β1 is Related to Portal Vein Thrombosis in Cirrhosis by Promoting Hypercoagulability and Endothelial Dysfunction

Prevalence and Clinical Significance of Portal Vein Thrombosis in Cirrhotic Patients with Acute Decompensation

Portal Vein Thrombosis Can Aggravate Esophageal Variceal Bleeding After Endoscopic Variceal Ligation

Treatment of portal vein thrombosis in cirrhosis is associated with no survival advantage: a retrospective controlled study